Fuente: FierceBiotech Just as a disciplined soccer player might pass on a hopeful shot in favor of better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms and predicted a “continued, albeit disciplined” recovery in 2026, according to a fourth-quarter PitchBook report on biopharma trends.